» Articles » PMID: 25205654

MiR200c Attenuates P-gp-mediated MDR and Metastasis by Targeting JNK2/c-Jun Signaling Pathway in Colorectal Cancer

Overview
Journal Mol Cancer Ther
Date 2014 Sep 11
PMID 25205654
Citations 38
Authors
Affiliations
Soon will be listed here.
Abstract

MicroRNA-200c (miR200c) recently emerged as an important regulator of tumorigenicity and cancer metastasis; however, its role in regulating multidrug resistance (MDR) remains unknown. In the current study, we found that the expression levels of miR200c in recurrent and metastatic colorectal cancers were significantly lower, whereas the JNK2 expression was higher compared with primary tumors. We showed that in MDR colorectal cancer cells, miR200c targeted the 3' untranslated region of the JNK2 gene. Overexpression of miR200c attenuated the levels of p-JNK, p-c-Jun, P-gp, and MMP-2/-9, the downstream factors of the JNK signaling pathway, resulting in increased sensitivity to chemotherapeutic drugs, which was accompanied by heightened apoptosis and decreased cell invasion and migration. Moreover, in an orthotopic MDR colorectal cancer mouse model, we demonstrated that overexpression of miR200c effectively inhibited the tumor growth and metastasis. At last, in the tumor samples from patients with locally advanced colorectal cancer with routine postsurgical chemotherapy, we observed an inverse correlation between the levels of mRNA expression of miR200c and JNK2, ABCB1, and MMP-9, thus predicting patient therapeutic outcomes. In summary, we found that miR200c negatively regulated the expression of JNK2 gene and increased the sensitivity of MDR colorectal cancer cells to chemotherapeutic drugs, via inhibiting the JNK2/p-JNK/p-c-Jun/ABCB1 signaling. Restoration of miR200c expression in MDR colorectal cancer may serve as a promising therapeutic approach in MDR-induced metastasis.

Citing Articles

MiRNAs: main players of cancer drug resistance target ABC transporters.

Mohammadi F, Nejatollahi M, Sheikhnia F, Ebrahimi Y, Mohammadi M, Rashidi V Naunyn Schmiedebergs Arch Pharmacol. 2025; .

PMID: 39808313 DOI: 10.1007/s00210-024-03719-y.


Drug resistance mechanisms in cancers: Execution of pro-survival strategies.

Dhanyamraju P J Biomed Res. 2024; 38(2):95-121.

PMID: 38413011 PMC: 11001593. DOI: 10.7555/JBR.37.20230248.


Bioinformatics analysis and experimental validation identified HMGA2/microRNA-200c-3p/LSAMP/Wnt axis as an immunological factor of patients with colorectal cancer.

Xu X, Gong C, Wang Y, Yin Z, Wang X, Hu Y Am J Cancer Res. 2023; 13(9):3898-3920.

PMID: 37818072 PMC: 10560921.


The role of lncRNA H19 in tumorigenesis and drug resistance of human Cancers.

Zhang X, Luo M, Zhang J, Guo B, Singh S, Lin X Front Genet. 2022; 13:1005522.

PMID: 36246634 PMC: 9555214. DOI: 10.3389/fgene.2022.1005522.


P-glycoprotein: new insights into structure, physiological function, regulation and alterations in disease.

Ahmed Juvale I, Abdul Hamid A, Abd Halim K, Che Has A Heliyon. 2022; 8(6):e09777.

PMID: 35789865 PMC: 9249865. DOI: 10.1016/j.heliyon.2022.e09777.